Seratrodast

Seratrodast
Clinical data
Trade names	Bronica in Japan, Changnuo, Mai Xu Jia, Quan Kang Nuo in China and as Seradair in India. .
AHFS/Drugs.com	International Drug Names
Routes of; administration	By mouth (tablets, granules)
ATC code	R03DX06 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	>96%
Elimination half-life	22 hours
Identifiers
	IUPAC name 7-Phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid;
CAS Number	112665-43-7 ;
PubChem CID	2449;
ChemSpider	2355 ;
UNII	4U58JM421N;
KEGG	D01123 ;
CompTox Dashboard (EPA)	DTXSID4021397 ;
ECHA InfoCard	100.220.176
Chemical and physical data
Formula	C22H26O4
Molar mass	354.446 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(=O)C(=C(C1=O)C)C(CCCCCC(=O)O)C2=CC=CC=C2)C;
	InChI InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24) ; Key:ZBVKEHDGYSLCCC-UHFFFAOYSA-N ;
	(what is this?) (verify)

Seratrodast (development name, AA-2414; marketed originally as Bronica) is a thromboxane A₂ (TXA₂) receptor (TP receptor) antagonist used primarily in the treatment of asthma. It was the first TP receptor antagonist that was developed as an anti-asthmatic drug and received marketing approval in Japan in 1997. As of 2017 seratrodast was marketed as Bronica in Japan, and as Changnuo, Mai Xu Jia, Quan Kang Nuo in China.

Unlike thromboxane synthase inhibitors such as ozagrel, seratrodast does not affect thrombus formation, time to occlusion and bleeding time. Seratrodast has no effect on prothrombin time and activated partial thromboplastin time, thus ruling out any action on blood coagulation cascade.